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Abstract: Background: Experience in real clinical practice with ceftazidime-avibactam for the
treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant
Enterobacterales (CRE) is very limited. Methods: We carried out a retrospective multicenter study of
patients hospitalized in 13 Italian hospitals who received ≥72 h of ceftazidime-avibactam for GNB
other than CRE to assess the rates of clinical success, resistance development, and occurrence of
adverse events. Results: Ceftazidime-avibactam was used to treat 41 patients with GNB infections
other than CRE. Median age was 62 years and 68% of them were male. The main causative
agents were P. aeruginosa (33/41; 80.5%) and extended spectrum beta lactamase (ESBL)-producing
Enterobacterales (4/41, 9.8%). Four patients had polymicrobial infections. All strains were susceptible
to ceftazidime-avibactam. The most common primary infection was nosocomial pneumonia (n = 20;
48.8%), primary bacteremia (n = 7; 17.1%), intra-abdominal infection (n = 4; 9.8%), and bone infection
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(n = 4; 9.8%). Ceftazidime-avibactam was mainly administered as a combination treatment (n = 33;
80.5%) and the median length of therapy was 13 days. Clinical success at the end of the follow-up
period was 90.5%, and the only risk factor for treatment failure at multivariate analysis was receiving
continuous renal replacement therapy during ceftazidime-avibactam. There was no association
between clinical failures and type of primary infection, microbiological isolates, and monotherapy
with ceftazidime-avibactam. Only one patient experienced recurrent infection 5 days after the end of
treatment. Development of resistance to ceftazidime-avibactam was not detected in any case during
the whole follow-up period. No adverse events related to ceftazidime-avibactam were observed in
the study population. Conclusions: Ceftazidime-avibactam may be a valuable therapeutic option for
serious infections due to GNB other than CRE.
Keywords: carbapenem-sparing regimen; ceftazidime-avibactam; Pseudomonas aeruginosa;
ESBL-producing Enterobacterales; nosocomial pneumonia
1. Introduction
The increasing incidence of infections caused by multidrug-resistant gram-negative bacteria
(MDR-GNB), such as Pseudomonas aeruginosa, Acinetobacter baumannii, or members of the order
Enterobacterales, has dramatically hindered the selection of an appropriate antimicrobial therapy,
leading to an increase in morbidity and mortality in patients with such infections [1–4].
Ceftazidime-avibactam is a new β-lactam/β-lactamase inhibitor currently approved by the
European Medicines Agency for the treatment of complicated intra-abdominal infections [5,6],
complicated urinary tract infections [7], hospital-acquired pneumonia (including ventilator-associated
pneumonia), and more generally, for aerobic gram-negative infections with limited treatment options [8].
In real-life experiences, high rates of favorable response to ceftazidime-avibactam treatment are reported
in patients with infections due to carbapenem−resistant Enterobacterales (CRE), with an overall success
rate of about 70% [9–15], whereas post-marketing experience regarding the use of ceftazidime-avibactam
for infections due to MDR-GNB other than CRE remains scarce [16–18] Moreover, information regarding
features associated with clinical failures and the emergence of resistance in this group of patients are
even scarcer. For this reason, in this multicenter study we describe our experience about the use of
ceftazidime-avibactam for the treatment of infections due to MDR-GNB other than CRE in 13 Italian
hospitals. More specifically, the primary objective of the study was to describe the rate of clinical cure
in the study population. The secondary objectives were to describe: (i) the characteristics of patients
who experienced clinical failure; (ii) resistance development rate; (iii) adverse events (AE) related to
ceftazidime-avibactam treatment.
2. Results
2.1. Baseline Characteristics
A total of 41 consecutive patients treated with ≥72 h of ceftazidime-avibactam for MDR-GNB
infections other than CRE were included in the study. Their baseline characteristics are presented
in Table 1. Their median age was 62 years (interquartile range (IQR) 41–70) and 68% (28/41) were
male. The most common underlying condition was cardiovascular disease (n = 14, 34.1%) followed
by chronic renal failure (n = 9, 22.0%). In 34 patients (82.9%) more than one underlying disease was
present, and the median Charlson comorbidity index was 4 (IQR 2–6). As many as 24 patients (58.5%)
presented with sepsis or septic shock and 10 of them were admitted to the intensive care unit (ICU)
due to the gram-negative infection.
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Table 1. Baseline demographics and clinical characteristics.
Variables n = 41
Age (years), median (IQR) 62 (41–70)
Sex, male, n (%) 28 (68.3)
Ward, n (%)
Medical 17 (41.5)
Surgical 7 (17.1)
Intensive care unit 17 (41.5)
Underlying disease, n (%)
Cardiovascular disease 14 (34.1)
Chronic renal disease 9 (22.0)
Diabetes mellitus 8 (19.5)
Solid organ transplant 8 (19.5)
Neurological disease 7 (17.1)
Solid organ tumors 7 (17.1)
Bronchiectasis 6 (14.6)
Chronic obstructive pulmonary disease 5 (12.2)
Gastrointestinal disease 4 (9.8)
Hematological malignancy 4 (9.8)
Charlson comorbidity index, mean (±SD) 4 (2–6)
Other predisposing conditions #, n (%)
Corticosteroids 12 (29.3)
Chemotherapy 7 (17.1)
Neutropenia (absolute neutrophil count <500 mm3) 5 (12.2)
Invasive procedures/devices, n (%)
Central venous catheter 29 (70.7)
Urinary catheter 26 (63.4)
Previous surgery # 15 (36.6)
Mechanical ventilation 14 (34.1)
Percutaneous endoscopic gastrostomy 2 (4.9)
Severity of clinical presentation, n (%)
No sepsis 17 (41.5)
Sepsis 17 (41.5)
Septic shock 7 (17.1)
ICU admission due to the index infection n (%) 10 (24.4)
# Within previous 30 days. Other infections include: 1 Central venous catheter-(CVC) related bacteremia;
1 pyelonephritis, 1 malignant external otitis, and 1 endocarditis. IQR, interquartile range; ICU, intensive care unit.
Types of primary infection and causative microorganisms are presented in Table 2. Overall,
nosocomial pneumonia (n = 20; 48.8%), primary bacteremia (n = 7; 17.1%), intra-abdominal infection
(n = 4; 9.8%), and bone infection (n = 4; 9.8%) were the most common types of infection. Overall
65% (13/20) and 35% (7/20) of nosocomial pneumonia cases were ventilator associated and hospital
acquired, respectively.
2.2. Microbiology
Thirty-seven of the 41 episodes were monomicrobial, whereas four were caused by more than one
MDR-GNB, leading to a total of 45 isolates from 41 patients. As shown in Table 3, isolated organisms
were P. aeruginosa (n = 38) and Enterobacterales (n = 7). All Enterobacterales isolates were phenotypically
classified as extended spectrum beta lactamase (ESBL)-producing strains.
Almost 90% of isolates were non-susceptible to cefepime, ceftazidime, ciprofloxacin, and
piperacillin-tazobactam. In addition, 11% of isolates were non-susceptible to ceftolozane-tazobactam
and 26.6% were non-susceptible to colistin. According to their susceptibility profiles, 11 isolates (24.4%)
were classified as MDR, 25 (55.6%) as extremely drug resistant (XDR), and 9 (20.0%) as pandrug
resistant (PDR).
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Table 2. Type of primary site of infection and causative agents.
Primary Site of Infection & Overall P. Aeruginosa
ESBL−Producing
Enterobacterales Polymicrobial
Nosocomial pneumonia 20 (48.8) 18 0 2 *
Primary bacteremia 7 (17.1) 5 1 1 ±
Intra-abdominal infection 4 (9.8) 2 1 1 #
Bone infection 4 (9.8) 3 1 0
Acute bacterial skin and skin structure infection 2 (4.9) 2 0 0
Other infections § 4 (9.8) 3 1 0
Total 41 33 4 4
& Seven patients (17.1%) had concomitant bacteremia. The portal of entries were lungs (2), abdomen (2), kidney (1), heart (1), and mediastinum (1); * Two mixed ventilator associated
pneumonia (VAP) [extended spectrum beta lactamase (ESBL) Enterobacteriaceae + P. aeruginosa]; ± One mixed intra-abdominal infection (IAI) due to P. aeruginosa and A. baumannii; # One
mixed bloodstream infection (BSI) due to P. aeruginosa and ESBL producing Enterobacteriaceae; § Other infections include: 1 CVC related bacteremia; 1 pyelonephritis, 1 malignant external
otitis, and 1 endocarditis.
Table 3. Susceptibility test results of 45 non-Enterobacterales (CRE) multidrug-resistant gram-negative bacteria (MDR-GNB) isolates from 41 patients.
Non-Susceptible Isolates, n (%)
Antibiotic Overall (n = 45) P. Aeruginosa (n = 38) ESBL-producing Enterobacterales (n = 7)
Amikacin 25 (55.6) 20 (52.6) 5 (71.4)
Cefepime 43 (95.6) 36 (94.7) 7 (100)
Ceftazidime 40 (88.9) 33 (86.8) 7 (100)
Ceftolozane-tazobactam 5 (11.1) 4 (10.5) 1 (14.8)
Ciprofloxacin 41 (91.1) 34 (89.4) 7 (100)
Colistin 12 (26.6) 12 (31.5) 0
Gentamycin 34 (75.6) 29 (76.3) 5 (71.4)
Imipenem 35 (77.8) 35 (92.1) 0
Meropenem 33 (73.3) 33 (86.8) 0
Piperacillin-tazobactam 39 (86.7) 34 (89.4) 5 (71.4)
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2.3. Characteristics of Ceftazidime-Avibactam Therapy
Twenty−seven patients (65.9%) received ceftazidime-avibactam as secondary therapy with the
median time for switching to ceftazidime-avibactam as 11 days of treatment with other agents (IQR
4.5–13 days) (Table 4). Piperacillin-tazobactam (48.1%, (13/27)), carbapenems (25.9%, (7/27)), and
colistin (22.2%; (6/27)) were the three most common antimicrobials prescribed prior to initiation
of ceftazidime-avibactam.
The main reason for switching to ceftazidime-avibactam was antimicrobial resistance to previous
antibiotic therapy in 25/41 patients (61.0%) and failure of previous antibiotic treatment in 14/41
patients (34.1%). Most patients received ceftazidime-avibactam treatment in combination with other
antibiotics (n = 33; 80.5%), that mainly included intravenous colistin (n = 12), aminoglycosides (n = 11),
carbapenems (n = 5), or fosfomycin (n = 5). The median duration of ceftazidime-avibactam treatment
was 13 (range 3–49) days.
Source control of infection was necessary in 13/41 patients (31.7%) and adequate in 11 of
them (84.6%).
Table 4. Previous treatment characteristics and ceftazidime-avibactam treatment information.
VARIABLE n = 41
Antibiotics before ceftazidime-avibactam for the current infection
Received antibiotics before ceftazidime-avibactam, n (%) 27 (65.9)
Number of antibiotics received, median (IQR) 1 (1–2)
Days of antibiotic therapy, median (IQR) 11 (4.5–13)
Main reason for ceftazidime-avibactam use
Antimicrobial resistance to previous antibiotic 25 (61.0)
Previous antibiotic failure 14 (34.1)
Previous colonization with carbapenemase-producing microorganisms 10 (24.4)
Ceftazidime-avibactam treatment
Targeted therapy 33 (80.5)
Empirical therapy 8 (19.5)
Combination therapy 33 (80.5)
Continuous renal replacement therapy 5 (12.2)
Days of treatment, median (range) 13 (3–49)
Intermittent infusion 26 (63.4)
Continuous infusion 2 (4.9)
Extended infusion 13 (31.7)
Adequate source control of the infection, n (%) 11/13 (84.6)
Clinical cure, n (%) 37 (90.2)
2.4. Clinical Cure
Among the 41 patients treated with ceftazidime-avibactam, clinical cure was achieved in 37
(90.2%). Clinical cure rates stratified according to the different types of infection are shown in Figure 1.
With regard to the two most common types of infection, clinical cure was achieved in 90% of patients
with nosocomial pneumonia (18/20) and 86% of patients with primary bacteremia (6/7). Stratification of
clinical cure rates according to the causative microorganisms is presented in Figure 2. The clinical cure
rates were 87.8%, 100%, and 100%, in patients with P. aeruginosa (29/33), ESBL-producing Enterobacterales
(4/4), and polymicrobial infection (4/4), respectively.
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2.5. Risk factors for Clinical Failures
Details of the four patients who experienced clinical failure are presented in Table 5 and
Suppleme tary Materials.
In order to identify predictors of treatment failure, univariate and multivariate analyses were
performed after adjusting for confounding factors (Table 6). The only factor related to clinical failure
was receipt of continuous renal replacement therapy at the time of infection onset (odds ratio (OR)
29.03, 95% CI 1.69–498.35; p = 0.02).
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Table 5. Description of patients who experienced clinical failure.
Age/Sex Underlying Condition Type of Infection ConcomitantBSI
Clinical
Presentation
Prior Therapy
to C/A Dose of C/A CRRT
Other
Interventions
Reason for
Clinical Failure
73/F
Wide intestinal resection and
hemicolectomy for intestinal
obstruction due to metastatic
colon cancer; pulmonary
embolism; CHF
PDR P. aeruginosa
Intra−abdominal
infection
No Sepsis No 1.25 gr/8 h for8 weeks Yes.
Inadequate source
control of the
infection;
concomitant colistin
therapy
Lack of clinical
response
57/F Systemic sclerosis; lungtransplant; chronic renal failure
XDR P. aeruginosa
Nosocomial
pneumonia
No No sepsis No 2.5 gr/8 h for10 days No
No concomitant
antibiotics
Lack of clinical
response
41/M Burn injury; acute kidney injury XDR P. aeruginosaPrimary bacteremia Yes Septic shock No
1.25 gr/8 h for
10 days Yes
No concomitant
antibiotic therapy
Recurrent
infection
76/M Diabetes; CHF; urothelialcarcinomas
XDR P. aeruginosa
Nosocomial
pneumonia
No
Sepsis
requiring ICU
admission
Meropenem
and amikacin
for 5 days
1.25 gr/8 h for
4 days Yes
Concomitant
amikacin Death
C/A, ceftazidime avibactam; BSI, bloodstream infection; CHF, chronic heart failure; CRRT, continuous renal replacement therapy; PDR, pandrug resistant; XDR, extremely drug resistant.
Table 6. Predictors of clinical failure of ceftazidime-avibactam therapy in the study population.
Univariate Analysis Multivariate Analysis
VARIABLE Successful ClinicalOutcome (n = 37) Clinical Failure (n = 4) p-Value OR (95% CI) p-Value
Age (years), mean ± SD 56.3 ± 18.4 61.7 ± 16.1 0.59 1.0 (0.88–1.13) 0.96
Sex, male, n (%) 25 (67.6) 3 (75.0) 1 −
Charlson comorbidity index, mean (±SD) 3.9 ± 3.0 6.2 ± 6.0 0.22 −
Underlying disease, n (%) −
Cardiovascular disease 12 (32.4) 2 (50.0) 0.59 −
Chronic renal disease 8 (21.6) 1 (25.0) 1 −
Diabetes mellitus 7 (18.9) 1 (25.0) 1 −
Solid organ transplant 7 (18.9) 1 (25.0) 1 −
Neurological disease 7 (18.9) 0 1 −
Solid organ tumors 5 (13.5) 2 (50.0) 0.12 6.09 (0.30–123.61) 0.42
Bronchiectasis 6 (16.2) 0 1 − −
Chronic obstructive pulmonary disease 5 (13.5) 0 1 − −
Gastrointestinal disease 4 (10.8) 0 1 − −
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Table 6. Cont.
Univariate Analysis Multivariate Analysis
VARIABLE Successful ClinicalOutcome (n = 37) Clinical Failure (n = 4) p-Value OR (95% CI) p-Value
Hematological malignancy 4 (10.8) 0 1 − −
Other predisposing conditions #, n (%) − −
Corticosteroids 11 (29.7) 1 (25.0) 1 − −
Chemotherapy 7 (18.9) 0 1 − −
Neutropenia (absolute neutrophil count <500 mmc3) 5 (13.5) 0 1 − −
Invasive procedures, n (%) #
Central venous catheter 25 (67.6) 4 (100) 0.30 − −
Urinary catheter 23 (62.2) 3 (75.0) 1 − −
Previous surgery 12 (32.4) 3 (75.0) 0.13 − −
Mechanical ventilation 11 (29.7) 3 (75.0) 0.10 3.74 (0.14–95.89) 0.42
Percutaneous endoscopic gastrostomy 2 (5.4) 0 1 − −
Severity of clinical presentation, n (%)
No sepsis 16 (43.2) 1 (25.0) 0.14 − −
Sepsis 15 (40.5) 2 (50.0) 1 − −
Septic shock 6 (16.2) 1 (25.0) 0.54 − −
Intensive care unit admission due to gram negative
infection n (%) 9 (24.3) 1 (25.0) 1 − −
Type of infection, n (%) −
Nosocomial pneumonia 18 (48.6) 2 (50.0) 1 −
Primary bacteremia 6 (16.2) 1 (25.0) 0.54 − −
Intra-abdominal infection 3 (8.1) 1 (25.0) 0.34 − −
Bone infection 4 (10.8) 0 1 − −
Acute bacterial skin and soft tissue infection 2 (5.4) 0 1 − −
Other infections § 4 (10.8) 0 1 − −
Microorganisms
P. aeruginosa 342 (81.1) 4 (100) 1 − −
Enterobacteriaceae 7 (18.9) 0 − −
C/T treatment
Combination therapy 31 (83.8) 2 (50.0) 0.16 − −
Empirical therapy 7 (18.9) 1 (25.0) 1 − −
Intermittent hemodialysis 2 (5.4) 2 (25.0) 0.27 − −
Continuous renal replacement therapy 2 (5.4) 3 (75.0) 0.004 29.03 (1.69−498.35) 0.02
Intermittent Infusion 23 (62.2) 3 (75.0) 1 − −
Continuous infusion 2 (5.4) 0 1 − −
Extended infusion 12 (32.4) 1 (25.0) 1 − −
Adequate source control of the infection, n (%) 9 (81.8) 2 (100) 1 − −
# Within previous 30 days; § Other infections include: 1 CVC related bacteremia; 1 pyelonephritis, 1 malignant external otitis, and 1 endocarditis. OR, odds ratio; CI, confidence interval;
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2.6. Adverse Events
Development of resistance to ceftazidime-avibactam was not detected in any patients
during the whole follow-up period. With regard to treatment safety, no adverse events were
observed in the study population that were deemed by the treating physicians to be related to
ceftazidime-avibactam treatment.
3. Discussion
This study is the largest evaluation of a cohort of patients treated with ceftazidime-avibactam for
different types of infections due to GNB other than carbapenems-resistant Enterobacterales. In line with
the pooled clinical cure rate observed in prior trials (85%) [19], about 90% of all assessed patients in
our study were deemed an overall treatment success at the end of ceftazidime-avibactam treatment.
Notably, this high clinical cure rate was observed despite our study population having a higher
prevalence of infections caused by MDR, XDR, or PDR pathogens, underlying comorbidities and use
of ceftazidime-avibactam as secondary therapy. Our findings also corroborate previous data reporting
renal replacement therapy as a risk factor for clinical failure of ceftazidime-avibactam therapy. Finally,
there were no reported adverse events deemed to be related to the drug by the treating physicians.
GNB are common in severe healthcare-associated infections, such as nosocomial pneumonia,
bloodstream infection (BSI), or intra-abdominal infection (IAI) [20]. Due to the high proportion of
MDR gram-negative pathogens [21], the greatest challenge in managing such infections today is the
increased need to use the last-line agents such as carbapenems; thus promoting the selection and
spread of more carbapenem-resistant strains. Therefore, the search for alternatives to carbapenems for
infections caused by multidrug resistant GNB is a clinical priority.
In the absence of porin deficient mutations or efflux pumps, gram-negative resistance to pivotal
antibiotics in our area is mainly mediated by the production of β-lactamases, such as class A (such as
ESBL, KPC), class C (AmpC), and some class D enzymes (e.g., OXA 48) [22]. None of these affects
ceftazidime-avibactam [23] and this context represents, in our opinion, the situation in which the drug
could be used as an alternative to carbapenem for the treatment of MDR gram-negative pathogens [24].
Although real-life experiences of ceftazidime-avibactam for the treatment of CRE is
accumulating [9–15], data regarding its effectiveness and safety for the treatment of other gram-negative
infections remain rare [16–18] and, to the best of our knowledge, are limited to only three single-center
retrospective studies including a total of 20 patients. In the largest of these analyses, Santevecchi et al. [17]
reported a clinical success rate of 70% in ten multidrug resistant gram-negative infections treated with
ceftazidime-avibactam. In our study, we report an overall clinical success rate of 90%. The high rate
of patients receiving continuous or intermittent infusion of ceftazidime-avibactam (40%) as well as
combination therapy in 80.5% of patients may have contributed to the clinical success observed in
our experience.
Interestingly, we found no significant differences in outcome when analyzed according to primary
cultured pathogens, with success rates up to 100% for ESBL-producing Enterobacterales infections.
In the case of ESBL strains, old β-lactams/β-lactamase inhibitors, such as piperacillin-tazobactam
or amoxicillin-clavulanic acid, were considered for many years as carbapenem-sparing options for
infections caused by ESBL-producing Enterobacterales [25–27]. However, based on the results from
the recent MERINO trial, piperacillin-tazobactam should not be longer considered as an alternative to
meropenem for bloodstream infections caused by ESBL strains [28].
Recently, based on in vitro studies, some authors have emphasized the use of
ceftazidime-avibactam as a potential carbapenem-sparing treatment for infections due to
ESBL−producing Enterobacterales [29–31]. However, experience in real clinical practice with
ceftazidime-avibactam for these infections remains limited. In the present study, including four and
two patients with monomicrobial and polymicrobial infections due to ESBL-producing Enterobacterales,
respectively, we report an excellent clinical success, even higher than the results obtained in the
early pivotal trials, that mainly included patients with complicated urinary tract infection (cUTI)
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or IAI [6–8]. Our results, should be confirmed in larger samples to more firmly explore the role of
ceftazidime-avibactam for the targeted treatment of patients with infections due to ESBL−producing
Enterobacterales as a possible carbapenem-sparing agent in selected cases, balancing this possibility
with that of reserving it for carbapenem-resistant strains.
Predictors of clinical failure in our study are in accordance with the results of a recent retrospective
analysis including patients with CRE infections, which showed that receiving continuous renal
replacement therapy was the greatest predictor for clinical failure [12]. From a clinical point of view, we
suggest closely monitoring drug serum concentrations in all patients receiving ceftazidime-avibactam
for serious gram-negative infections during continuous renal replacement therapy. More data are
needed to clarify which is the adequate dosage of ceftazidime-avibactam in patients receiving continuous
renal replacement therapy.
One of the most concerning issue related to ceftazidime-avibactam therapy is the rate of
recurrence and the appearance of ceftazidime-avibactam resistance during or after treatment [12].
In their study, Santavecchi et al. [17] described the emergence of resistance while on therapy with
ceftazidime-avibactam in 2 out of 10 patients (20%) who were treated for 50 and 13 days, respectively.
In our study, although with the limitations of the non-standardized collection of follow-up samples, no
resistance to ceftazidime-avibactam was detected. In our opinion, further studies are needed to clarify
whether combination treatment plays a protective role against the emergence of resistance.
Consistent with previous reports [17,32], we were unable to detect adverse drug events related to
ceftazidime-avibactam treatment, even when the drug was administered for a relatively prolonged
period of time (median of 13 days (range 2–49 days)). However, due to the retrospective nature of our
data we are limited to that information reported in the medical records.
Our study has other limitations that should be addressed. First, this was an observational
non-comparative study and thus the typical limitations of this study design apply, including the
potential effects of unmeasured data, the lack of a control group, and possible confounding factors.
Second, although this is the largest experience reported to date, the limited number of patients reported
in this study represents an obvious limitation to the extrapolability of our results. Third, our follow-up
period may be considered too short for evaluating recurrence, especially in the case of infections such
as primary bacteremia or bone infections. Fourth, due to its retrospective nature, we were not able to
collect information about when clinicians obtained susceptibility results to ceftazidime-avibactam.
In conclusion, in this observational study ceftazidime-avibactam showed high clinical cure rates
when used for treating serious infections caused by MDR-GNB other than CRE. Further studies remain
warranted to more comprehensively evaluate the possible role of ceftazidime-avibactam as a targeted
carbapenem-sparing option.
4. Materials and Methods
This is a multicenter, retrospective case series of all adult patients who received
ceftazidime-avibactam for ≥72 h for documented infections caused by MDR−GNB other than CRE in
13 hospitals located in 9 Italian regions (Friuli Venezia Giulia, Veneto, Lombardia, Piemonte, Emilia
Romagna, Liguria, Lazio, Puglia, and Sicilia). The study was conducted from 1 July 2017 to 31 July 2019.
Patients were included in the study if they had a documented infection caused by at least one
GNB other than CRE. Patients were excluded if: (i) ceftazidime-avibactam was used for prophylactic
purpose; (ii) they had an infection caused by non MDR-GNB according to antibiotic susceptibility
testing; or (iii) they had an infection caused by a CRE.
The study was approved by the ethics committee of the coordinating center (Azienda Ospedaliera
Universitaria Integrata di Udine).
4.1. Definitions and Data Collection
All patients were followed-up for at least 30 days after ceftazidime-avibactam therapy was
discontinued. Clinical assessments were determined at the end of the follow-up period. Clinical
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outcomes were characterized as follows: cure, patients had complete resolution of clinical signs and
symptoms related to the infection and/or infection cleared with no positive cultures reported at the end
of ceftazidime-avibactam therapy; and failure, lack of clinical response and/or death due to infection
and/or recurrent infection.
Documented infection was defined as isolation of MDR−GNB other than CRE in presence of signs and
symptoms of infection. MDR, XDR, and PDR were defined according to criteria and Magiorakos et al. [33].
Ceftazidime-avibactam was administered at the standard dosage of 2.5 gm IV q8 h. Dose
adjustment was required only for patients with moderate renal dysfunction (creatinine clearance
(CLCr) <50 mL/min).
AE related to ceftazidime-avibactam treatment were defined as AE that occurred during the
period which elapsed from initiation of ceftazidime-avibactam therapy to 30 days after discontinuation
of ceftazidime-avibactam therapy, and that were deemed by the treating physicians to be related to
ceftazidime-avibactam treatment (according to medical charts data).
The data collected from medical records included the following: age; sex; ward of stay at
the onset of infection; underlying diseases; Charlson comorbidity index [34]; type of infection
(according to the Centers for Disease Control and Prevention criteria [35]); presence of sepsis and
septic shock (defined according to Sepsis 3 criteria [36]); causative organism and susceptibility test
results; other antibiotics administered before, concomitant, and after ceftazidime-avibactam; reasons
for ceftazidime-avibactam use; type of ceftazidime-avibactam therapy (first-line vs. second-line
therapy; empirical vs. targeted therapy; monotherapy vs. combination therapy), duration of
ceftazidime-avibactam therapy; adequateness of source control where applicable (source control was
defined as adequate in case of: (i) removal of intravascular catheters in patients with bacteremia;
(ii) surgical or radiological drainage of infected fluid collection); adverse events.
Collected data were registered on an electronic case report form using REDCap (Research Electronic
Data Capture).
4.2. Microbiological Methods
Identification of the organisms was performed at each participating center according to their own
local practice. Susceptibility to antibiotics was also reported as interpreted by the local laboratories. Of
note: (i) ESBL-producing Enterobacterales were phenotypically identified using the following criteria:
minimum inhibitory concentration (MIC) ≥2 µg/L for a third-generation cephalosporin or meropenem
or MIC increase of ≥3 dilutions when combined with clavulanic acid; (ii) resistance to carbapenems in
Enterobacterales was defined as imipenem and/or meropenem MIC >4 µg/mL or ertapenem MICs of
>0.5 µg/mL [37]; (iii) in all participating centers, MIC values of ceftazidime-avibactam were determined
by E-test (bioMérieux, Marcy l’Etoile, France) and interpreted according to the current European
Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [37].
4.3. Statistical Analysis
Both the primary analysis (description of clinical cure rates in the entire study population and
in subgroups according to type of infection and causative agents, using numbers and percentages)
and the secondary analysis (description of the characteristics of patients who experienced clinical
failure and of adverse events related to ceftazidime-avibactam treatment) were descriptive and the
related results were reported in terms of numbers and percentages for categorical data and median
and interquartile range (IQR) for continuous data.
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